Evidence map›Paper›PMID 28315745›Full record

ArticleProtein expression and purification2017

Production of low-expressing recombinant cationic biopolymers with high purity.

Xuguang Chen, Alireza Nomani, Niket Patel, Arash Hatefi

Abstract read
In one paragraph

Article in Protein expression and purification, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. An OFrontiers in microbiology · 2023
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xuguang ChenDepartment of Pharmaceutics, Rutgers University, Piscataway, NJ 08854, United States.
Alireza NomaniDepartment of Pharmaceutics, Rutgers University, Piscataway, NJ 08854, United States.
Niket PatelDepartment of Pharmaceutics, Rutgers University, Piscataway, NJ 08854, United States.
Arash HatefiDepartment of Pharmaceutics, Rutgers University, Piscataway, NJ 08854, United States. Electronic address: ahatefi@pharmacy.rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian CancerR01CA175318 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI HATEFI, ARASH · 2015 to 2019
$1.8M
Bioengineering a Safe and Efficient Vector Technology for Stem Cell TransfectionR21EB016792 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI HATEFI, ARASH · 2014 to 2015
$426k
NCI NIH HHS R01 CA175318NIBIB NIH HHS R21 EB016792
6 · The paper itself

Abstract

The growing complexity of recombinant biopolymers for delivery of bioactive agents requires the ability to control the biomaterial structure with high degree of precision. Genetic engineering techniques have provided this opportunity to synthesize biomaterials in an organism such as E. coli with full control over their lengths and sequences. One class of such biopolymers is recombinant cationic biopolymers with applications in gene delivery, regenerative medicine and variety of other biomedical applications. Unfortunately, due to their highly cationic nature and complex structure, their production in E. coli expression system is marred by low expression yield which in turn complicates the possibility of obtaining pure biopolymer. SlyD and ArnA endogenous E. coli proteins are considered the major culprits that copurify with the low-expressing biopolymers during the metal affinity chromatography. Here, we compared the impact of different parameters such as the choice of expression hosts as well as metal affinity columns in order to identify the most effective approach in obtaining highly pure recombinant cationic biopolymers with acceptable yield. The results of this study showed that by using E. coli BL21(DE3) LOBSTR strain and in combination with our developed stringent expression and Ni-NTA purification protocols highly pure products in one purification step (>99% purity) can be obtained. This approach could be applied to the production of other complex and potentially toxic biopolymers with wide range of applications in biomedicine.

Indexed as

Carboxy-LyasesEscherichia coliEscherichia coli ProteinsGene ExpressionPeptidylprolyl IsomeraseCationsCarboxy-LyasesCationsEscherichia coli ProteinsPeptidylprolyl IsomeraseSlyD protein, E coliUDPglucuronate decarboxylaseBL21(DE3) LOBSTRCationic recombinant biopolymerHistidine tagHistone H2ALow expressing proteinSlyD

Identifiers

PMID28315745
PMCPMC5479735
OpenAlexW2596476966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.